The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: The survival benefit with adjuvant chemotherapy for patients with resected stage II-III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive biomarkers in these patients have not yielded clinically useful tests. We report findings from the Lung Adjuvant Cisplatin Evaluation (LACE)-Bio-II study, in which we analyzed next-generation sequencing and long-term outcomes data from > 900 patients with early-stage NSCLC treated prospectively in adjuvant landmark clinical trials. We used a targeted gene panel to assess the prognostic and predictive effect of mutations in individual genes, DNA repair pathways, and tumor mutation burden (TMB). Methods: A total of 908 unmatched, formalin-fixed, paraffin-embedded, resected lung cancer tumor specimens were sequenced using a targeted panel of 1,538 genes. Stringent filtering criteria were applied to exclude germline variants and artifacts related to formalin fixation. Disease-free survival, overall survival, and lung cancer—specific survival (LCSS) were assessed in Cox models stratified by trial and adjusted for treatment, age, sex, performance score, histology, type of surgery, and stage. Results: Nonsynonymous mutations were identified in 1,515 genes in 908 tumor samples. High nonsynonymous TMB (> 8 mutations/Mb) was prognostic for favorable outcomes (ie, overall survival, disease-free survival, and LCSS) in patients with resected NSCLC. LCSS benefit with adjuvant chemotherapy was more pronounced in patients with low nonsynonymous TMBs (≤ 4 mutations/Mb). Presence of mutations in DNA repair pathways, tumor-infiltrating lymphocytes, TP53 alteration subtype, and intratumor heterogeneity was neither prognostic nor predictive. Statistically significant effect of mutations in individual genes was difficult to determine due to high false-discovery rates. Conclusion: High nonsynonymous TMB was associated with a better prognosis in patients with resected NSCLC. In addition, the benefit of adjuvant chemotherapy on LCSS was more pronounced in patients with low nonsynonymous TMBs. Studies are warranted to confirm these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
A Direct Approach to False Discovery Rates
Storey, J. D. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00346 · Cited by 5,603
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Flexible regression models with cubic splines
Durrleman, S., & Simon, R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,689
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Self-citationStrauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4855 · Cited by 974
TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck
Poeta, M. L., Manola, J., Goldwasser, M. A., Forastiere, A., Benoit, N., Califano, J. A., Ridge, J. A., Goodwin, J., Kenady, D., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 817
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
BET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545
Butts, C. A., Ding, K., Seymour, L., Twumasi-Ankrah, P., Graham, B., Gandara, D., Johnson, D. H., Kesler, K. A., Green, M., Vincent, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0333 · Cited by 425
Self-citationMroz, E. A., & Rocco, J. W. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.09.007 · Cited by 417
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer
Brambilla, E., Le Teuff, G., Marguet, S., Lantuejoul, S., Dunant, A., Graziano, S., Pirker, R., Douillard, J.-Y., Le Chevalier, T., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 349
Self-citationClinical Relevance of Microsatellite Instability in Colorectal Cancer
de la Chapelle, A., & Hampel, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0652 · Cited by 332
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
Roth, A. D., Delorenzi, M., Tejpar, S., Yan, P., Klingbiel, D., Fiocca, R., d'Ario, G., Cisar, L., Labianca, R., Cunningham, D., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs427 · Cited by 284
Tsao, M.-S., Marguet, S., Le Teuff, G., Lantuejoul, S., Shepherd, F. A., Seymour, L., Kratzke, R., Graziano, S. L., Popper, H. H., Rosell, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8335 · Cited by 267
Self-citationWong, S. Q., Li, J., Tan, A. Y.-C., Vedururu, R., Pang, J.-M. B., Do, H., Ellul, J., Doig, K., Bell, A., McArthur, G. A., et al. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-23 · Cited by 247
Eguchi, T., Bains, S., Lee, M.-C., Tan, K. S., Hristov, B., Buitrago, D. H., Bains, M. S., Downey, R. J., Huang, J., Isbell, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0834 · Cited by 209
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
Nagaraj, A. B., Joseph, P., Kovalenko, O., Singh, S., Armstrong, A., Redline, R., Resnick, K., Zanotti, K., Waggoner, S., & DiFeo, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4690 · Cited by 195
Molina-Vila, M. A., Bertran-Alamillo, J., Gascó, A., Mayo-de-las-Casas, C., Sánchez-Ronco, M., Pujantell-Pastor, L., Bonanno, L., Favaretto, A. G., Cardona, A. F., Vergnenègre, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2391 · Cited by 181
Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
Self-citationTsao, M., Teuff, G. L., Shepherd, F. A., Landais, C., Hainaut, P. L., Filipits, M., Pirker, R., Chevalier, T. L., Graziano, S. L., Kratze, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx003 · Cited by 117
Self-citationOh, E., Choi, Y., Kwon, M. J., Kim, R. N., Kim, Y. J., Song, J., Jung, K. S., & Shin, Y. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144162 · Cited by 115
Ma, X., Teuff, G. L., Lacas, B., Tsao, M., Graziano, S. L., Pignon, J., Douillard, J.-Y., Chevalier, T. L., Seymour, L., Filipits, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.002 · Cited by 106
Self-citationPitfalls of Using Composite Primary End Points in the Presence of Competing Risks
Mell, L. K., & Jeong, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2802 · Cited by 68
Cited by
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Rakaee, M., Adib, E., Ricciuti, B., Sholl, L. M., Shi, W., Alessi, J. V., Cortellini, A., Fulgenzi, C. A. M., Viola, P., Pinato, D. J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4933 · Cited by 141
Berland, L., Heeke, S., Humbert, O., Macocco, A., Long-Mira, E., Lassalle, S., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Cohen, C., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.102 · Cited by 95
Metadata
- Authors
- Devarakonda, S., Rotolo, F., Tsao, M.-S., Lanc, I., Brambilla, E., Masood, A., Olaussen, K. A., Fulton, R., Sakashita, S., McLeer-Florin, A., Ding, K., Le Teuff, G., Shepherd, F. A., Pignon, J.-P., Graziano, S. L., Kratzke, R., Soria, J.-C., Seymour, L., Govindan, R., & Michiels, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-10-20
- Volume
- 36
- Issue
- 30
- Pages
- 2995-3006
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2885229054
- Cited by
- 272
- References
- 35
- FWCI
- 25.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.